NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Nurix Therapeutics statistics
Financials through Aug 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.59B | $166.30M |
| Enterprise Value | $1.49B | $88.19M |
| PE Ratio | 10.79 | 20.44 |
| PS Ratio | 3.69 | 3.65 |
| PB Ratio | 2.67 | 2.03 |
| P/TBV Ratio | 2.67 | 2.29 |
| P/FCF Ratio | 7.00 | 17.44 |
| P/OCF Ratio | 6.82 | 12.98 |
Enterprise value
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 2.12 | 2.51 |
| EV / EBITDA | 4.98 | 14.65 |
| EV / EBIT | 5.13 | 19.00 |
| EV / FCF | 4.02 | 20.86 |
Income (trailing twelve months)
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Revenue | $701.94M | $58.34M |
| Operating Income | $289.66M | -$21.40M |
| Net Income | $294.88M | -$22.46M |
| EBITDA | $298.37M | -$16.91M |
| EPS (Diluted) | $2.31 | -$0.83 |
Margins
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Operating Margin | 41.3% | -44.0% |
| Profit Margin | 42.0% | -40.2% |
| EBITDA Margin | 42.5% | -30.2% |
| FCF Margin | 52.7% | -9.27% |
Returns
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 44.0% | -53.2% |
| Return on Assets (ROA) | 34.3% | -40.9% |
| Return on Capital Employed (ROCE) | 27.2% | -38.1% |
Growth
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 738.8% | 5.96% |
| Revenue Growth (3Y CAGR) | 29.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 36.3% | 6.48% |
Balance sheet
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.10B | $61.43M |
| Net Cash (Debt) | $1.10B | $15.35M |
| Net Cash Per Share | $10.60 | $0.66 |
| Equity (Book Value) | $968.31M | $49.09M |
| Book Value Per Share | $9.33 | $1.37 |
| Tangible Book Value | $968.31M | $23.52M |
| Working Capital | $972.95M | $76.81M |
Financial position
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.44 | 3.34 |
| Quick Ratio | 8.57 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $379.31M | -$12.35M |
| Capital Expenditures | -$9.50M | -$1.08M |
| Free Cash Flow | $369.81M | -$20.22M |
| FCF Per Share | $3.56 | -$0.42 |
Efficiency
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.82 | 0.39 |
| Revenue Per Employee | $2.21M | $404.87K |
| Profits Per Employee | $930.21K | -$703.34K |
| Employee Count | 317 | 74 |
Dividends and yields
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 11.4% | -23.3% |
| FCF Yield | 14.3% | -8.72% |
| Dividend Yield | 0.00% | 1.82% |
| Buyback Yield | -0.70% | -0.59% |
| Shareholder Yield | -0.70% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 103,782,000 | 58,127,000 |
| Shares Change (YoY) | 31.0% | 10.9% |
| Shares Change (QoQ) | 5.30% | 0.54% |
| Float | 100,296,000 | 49,136,700 |
| Shares Held by Insiders | 3.36% | 11.6% |
| Shares Held by Institutions | 113.1% | 59.4% |
Taxes
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Income Tax | $13.34M | $79.87K |
Scores
| Measure | Nurix Therapeutics | Industry median |
|---|---|---|
| Graham Number | $22.02 | $18.73 |
| Graham Upside | -11.7% | -45.1% |
| Altman Z-Score | 8.46 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Nurix Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.